SecBot SecBot
PRESS-RELEASE ·Filed Nov 2, 2026

INSP

Inspire Medical Systems
NEUTRAL
Impact 5/10
Horizonmonths Processed14d 7h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Revenue decline and GAAP loss are negative, but the adjusted EPS beat and narrowed guidance (higher low end) suggest stabilization. Watch for Q4 revenue trajectory and 2027 guidance for signs of recovery from coding headwinds; the 2028 CPT code change is a long-term catalyst.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$61.90
T+0 close · Nov 2, 2026 · via day close
Latest settled
+0.66%
T+5 · $62.31 · next T+20 in 15d
Vs SPY
+1.25%
α at T+5
Latest observation
+0.66%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $61.90entry
  2. T+1 · 13d ago +7.61%α +5.96% · $66.61
  3. T+5 · 7d ago +0.66%α +1.25% · $62.31
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Inspire Medical Systems reported Q3 2026 revenue of $206.7M, down 7.9% YoY, and adjusted diluted EPS of $0.14, beating the consensus estimate of $0.09. The company narrowed its full-year 2026 revenue guidance to $850M-$860M (from $835M-$875M) and maintained adjusted EPS guidance of $1.20-$1.40. Revenue decline was driven by coding and reimbursement headwinds, partially offset by higher-margin Inspire V mix and a new CPT code approval for 2028.

Key Financial Metrics

EPS (Adj.)
$0.14
est $0.09 · +55.6% · GAAP: $-0.84
Revenue
$206.7M
est $204.3M · +1.2% · -7.9% YoY
Rating
beat
Guidance
$850M-$860M
maintained
Gross Margin
86%

Key Facts

  • Q3 2026 revenue $206.7M, down 7.9% YoY from $224.5M
  • GAAP diluted EPS $(0.84); adjusted diluted EPS $0.14 (consensus $0.09, beat)
  • Operating loss $(28.7M); adjusted operating income $1.9M (0.9% margin)
  • Net loss $(24.4M) vs net earnings $9.9M in Q3 2025
  • Operating cash flow $46.4M, down from $68.5M YoY
  • Full-year 2026 revenue guidance narrowed to $850M-$860M (prior $835M-$875M)
  • Adjusted diluted EPS guidance maintained at $1.20-$1.40
  • AMA approved new Category I CPT code for single lead HGNS (Inspire V), effective Jan 1, 2028
  • Restructuring charges of $24.1M related to Project Horizon
  • Legal settlement expense of $7.0M for pixel-tracking class action

Financial Impact

Revenue decline of $17.8M YoY; adjusted EPS beat consensus by $0.05 (55.6% surprise); restructuring charges $24.1M; legal settlement $7.0M

revenueepsoperating incomecash flowgross margin

Risk Factors

  • Revenue declined 7.9% YoY due to coding and reimbursement challenges
  • GAAP net loss of $(24.4M) vs prior-year profit
  • Restructuring charges of $24.1M and legal settlement of $7.0M weigh on profitability
  • Operating cash flow declined 32% YoY
  • Full-year guidance implies Q4 revenue of $238M-$248M, requiring acceleration

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
38% bullish (24 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3393767

Track record

16 reports on INSP

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $59.52 Now $59.12 −0.67% settles Nov 17
  2. Nov 12, 20264d ago SC 13G/A Bearish 4/10 Entry $60.54 to $61.10 Now $59.12 +2.35% ▼ −0.93% −1.29% vs SPY
  3. Nov 9, 20267d ago Institutional Cluster Mixed 3/10 Entry $62.31 to $62.11 Now $59.12 −5.12% ▼ −0.32% −1.64% vs SPY
  4. Nov 9, 20267d ago SC 13G/A Bearish 4/10 Entry $62.31 to $62.11 Now $59.12 +5.12% ▲ +0.32% +1.64% vs SPY
  5. Nov 2, 202614d ago 8-K Mixed 6/10 No price data
  6. Nov 2, 202614d ago Press Release Neutral 5/10 Viewing Entry $61.90 to $66.61 Now $59.12 −4.49% ▲ +7.61% +5.96% vs SPY
  7. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $68.10 to $67.21 Now $59.12 −13.19% ▼ −1.31% −0.83% vs SPY
  8. Oct 5, 20266w ago Press Release Neutral 1/10 Entry $68.20 Now $59.12 −13.31% No price data
  9. Jul 27, 202616w ago 3 Neutral 1/10 Entry $51.97 to $51.07 Now $59.12 +13.76% ▼ −1.73% −0.19% vs SPY
  10. Jul 24, 202616w ago 8-K Neutral 2/10 Entry $50.93 to $51.97 Now $59.12 +16.08% ▲ +2.04% +1.80% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 9h 22m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026